Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis
City of Hope is one of the leading centers for novel cellular therapies. Slots for a Juno CAR-T CLL trial are now available. If you are a patient who has relapsed or refractory CLL (failed 2 or 3 lines of therapy) or who has progressed on ibrutinib AND is intolerant to ibrutinib, this is an opportunity to consider and to be considered for a CAR-T trial.
Please contact Lilly Li (jlillyli@coh.org or 626 359 8111 x80715) soon to find out more details, whether you qualify and if it makes sense as your next treatment.
Here is a link to the trial officially named
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory CLL or SLL (TRANSCEND-CLL-004)
https://clinicaltrials.gov/ct2/show/NCT03331198
February 21, 2018
Related posts